E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy

被引：41
|
作者：
Claudiani, Simone [1 ]
Apperley, Jane F. [1 ]
Gale, Robert Peter [1 ]
Clark, Richard [2 ]
Szydlo, Richard [1 ]
Deplano, Simona [1 ]
Palanicawandar, Renuka [1 ]
Khorashad, Jamshid [1 ]
Foroni, Letizia [1 ]
Milojkovic, Dragana [1 ]
机构：
[1] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Haematol, London, England
[2] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England
来源：
HAEMATOLOGICA | 2017年 / 102卷 / 08期
关键词：
CHRONIC MYELOGENOUS LEUKEMIA; MOLECULAR RESPONSE; YOUNG-ADULTS; IMATINIB; E13A2; TRIAL;
D O I：
10.3324/haematol.2017.168740
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E297 / E299
页数：3
相关论文
共 50 条
  • [1] Treatment-free remission in e19a2 BCR-ABL1 chronic myeloid leukemia
    Kajiguchi, Tomohiro
    Hashimoto, Ken
    Shimizu, Rie
    Okuno, Shingo
    Takagi, Erina
    ANNALS OF ONCOLOGY, 2021, 32 : S356 - S356
  • [2] BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure
    Kim, Dennis Dong Hwan
    Novitzky-Basso, Igor Nicolas
    Kim, Taehyung
    Atenafu, Eshetu G.
    Forrest, Donna L.
    Savoie, Lynn
    Bence-Bruckler, Isabelle
    Keating, Mary-Margaret
    Busque, Lambert
    Delage, Robert
    Xenocostas, Anargyros
    Liew, Elena
    Paulson, Kristjan
    Stockley, Tracy L.
    Laneuville, Pierre
    Lipton, Jeffrey H.
    Kamel-Reid, Suzanne
    Leber, Brian
    BLOOD, 2020, 136
  • [3] Treatment-Free Remission in Chronic Myeloid Leukemia Harboring Atypical BCR-ABL1 Transcripts
    Dragani, Matteo
    Petiti, Jessica
    Rege-Cambrin, Giovanna
    Gottardi, Enrico
    Daraio, Filomena
    Caocci, Giovanni
    Aguzzi, Chiara
    Crisa, Elena
    Andreani, Giacomo
    Caciolli, Francesca
    Fava, Carmen
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2020, 12
  • [4] e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response
    Marce, Silvia
    Mendez, Aleix
    Xicoy, Blanca
    Estrada, Natalia
    Cabezon, Marta
    Sturla, Antonella Luciana
    Garcia, Miriam Ratia
    Angona, Anna
    Amat, Paula
    Escribano Serrat, Silvia
    Scalzulli, Emilia
    Morgades, Mireia
    Senin, Alicia
    Hernandez-Boluda, Juan Carlos
    Ferrer-Marin, Francisca
    Anguita, Eduardo
    Cortes, Montserrat
    Plensa, Esther
    Breccia, Massimo
    Garcia-Gutierrez, Valentin
    Zamora, Lurdes
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (03)
  • [5] Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia
    El Missiry, Mohamed
    Hjorth-Hansen, Henrik
    Richter, Johan
    Olson-Stromberg, Ulla
    Stenke, Leif
    Porkka, Kimmo
    Kreutzman, Anna
    Mustjoki, Satu
    PLOS ONE, 2017, 12 (01):
  • [6] Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib
    Marce, Silvia
    Xicoy, Blanca
    Garcia, Olga
    Cabezon, Marta
    Estrada, Natalia
    Velez, Patricia
    Boque, Concepcion
    Sagues, Miguel
    Angona, Anna
    Teruel-Montoya, Raul
    Ferrer-Marin, Francisca
    Amat, Paula
    Hernandez-Boluda, Juan Carlos
    Ibarra, Mariana M.
    Anguita, Eduardo
    Cortes, Montserrat
    Fernandez-Ruiz, Andres
    Fontanals, Sandra
    Zamora, Lurdes
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (14)
  • [7] Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations
    Claudiani, Simone
    Apperley, Jane F.
    Khan, Afzal
    Khorashad, Jamshid
    Milojkovic, Dragana
    HAEMATOLOGICA, 2020, 105 (05) : E225 - E227
  • [8] BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
    Cuellar, Sandra
    Vozniak, Michael
    Rhodes, Jill
    Forcello, Nicholas
    Olszta, Daniel
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (06) : 433 - 452
  • [9] Improvement of Treatment-Free Remission Rate Following Discontinuation of BCR::ABL1 Tyrosine Kinase Inhibitors in Chronic Phase, Chronic Myeloid Leukemia
    Lee, Sewon
    Kim, Hongtae
    Lee, Semin
    Kim, Seunghoon
    Park, Sung-Ho
    Kim, Sung-Hyun
    Do, Young Rok
    Kim, Soo-Hyun
    Kee, Kyung-Mi
    Kim, Dong-Wook
    BLOOD, 2023, 142
  • [10] Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia
    Pinilla-Ibarz, Javier
    Sweet, Kendra
    Emole, Josephine
    Fradley, Michael
    ANTICANCER RESEARCH, 2015, 35 (12) : 6355 - 6364
12345